Group 1 - The core viewpoint of the news is that 泰恩康's stock has experienced a significant decline recently despite a substantial increase in its price year-to-date, indicating potential volatility in the market [1][2]. - As of September 23, 泰恩康's stock price was 33.84 yuan per share, with a market capitalization of 14.399 billion yuan [1]. - The company has seen a year-to-date stock price increase of 128.79%, but it has declined by 12.42% over the last five trading days [1]. Group 2 - 泰恩康's main business segments include pharmaceutical agency (65.16%), pharmaceutical manufacturing (31.70%), and pharmaceutical technology services (2.97%) [1]. - As of June 30, the number of shareholders decreased by 33.05% to 10,900, while the average circulating shares per person increased by 49.36% to 27,747 shares [2]. - For the first half of 2025, 泰恩康 reported a revenue of 347 million yuan, a year-on-year decrease of 12.23%, and a net profit of 37.084 million yuan, down 56.75% year-on-year [2]. Group 3 - Since its A-share listing, 泰恩康 has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [3].

据悉，泰恩康于2025年8月先后召开董事会、监事会及临时股东大会，审议通过2025年员工持股计划相 关议案，为计划落地奠定坚实基础。截至2025年9月22日，该计划通过二级市场集中竞价方式，累计买 入公司股票539.6243万股，占公司总股本的1.27%，成交总金额近1.98亿元（不含交易费用），成交均 价36.69元/股，实际认购份额严格控制在股东大会审议通过的上限范围内，操作合规且高效。 泰恩康此次员工持股计划的顺利落地，极大激发了创新活力与奋斗激情，为后续业务拓展、技术创新注 入更强动力。该计划的成功实施，有望成为驱动泰恩康实现新一轮高质量发展的新引擎。 此次员工持股计划覆盖公司（含控股子公司）董事、高级管理人员、核心骨干员工等关键群体，核心员 工以真金白银积极"加仓"公司股票，其行动本身即是对公司管理团队、核心竞争力和长远发展蓝图投下 的最有力"信任票"。根据公告，本次员工持股计划所购股票锁定期为12个月，自2025年9月22日起至 2026年9月21日止。 中证报中证网讯（王珞）9月22日，泰恩康（301263）（301263）发布公告，宣布公司2025年员工持股 计划已顺利完成股票购买，充分彰显对 ...

此次员工持股计划覆盖公司（含控股子公司）董事、高级管理人员、核心骨干员工等关键群体，核心员 工以真金白银积极"加仓"公司股票。根据公告，本次员工持股计划所购股票锁定期为12个月，自2025年 9月22日起至2026年9月21日止。 本报讯 （记者王镜茹）9月22日，广东泰恩康医药股份有限公司（以下简称"泰恩康"）发布公告，宣布 公司2025年员工持股计划已顺利完成股票购买，充分彰显对未来经营发展的坚定信心。 据悉，泰恩康于8月先后召开董事会、监事会及临时股东大会，审议通过2025年员工持股计划相关议 案，为计划落地打下坚实基础。截至9月22日，该计划通过二级市场集中竞价方式，累计买入公司股票 539.6243万股，占公司总股本的1.27%，成交总金额近1.98亿元（不含交易费用），成交均价36.69元/ 股，实际认购份额严格控制在股东大会审议通过的上限范围内，操作合规且高效。 公司董事长郑汉杰表示："员工持股计划圆满落地，是公司'以人为本、共享发展'理念的生动实践。员 工对公司未来战略前景的高度认同与坚定信心，是公司最宝贵的财富和无形的驱动力。我们将持续聚焦 核心战略，提升经营效能，以更亮眼的成绩回报全体股东 ...

（文章来源：证券日报） 证券日报网讯 9月22日晚间，泰恩康发布公告称，截至2025年9月22日，公司2025年员工持股计划（简 称"本持股计划"）已通过二级市场集中竞价方式累计买入公司股票5，396，243股，占公司总股本的 1.27%，成交金额合计197，967，478.50元（不含交易费用），成交均价为36.69元/股。本持股计划实际 认购份额未超过公司股东大会审议通过的拟认购份额上限，公司已完成本持股计划标的股票的购买。 ...

2025年9月22日，广东泰恩康医药股份有限公司（证券代码：301263，证券简称：泰恩康）发布公告， 宣布公司2025年员工持股计划已顺利完成股票购买，充分彰显对未来经营发展的坚定信心。 据悉，泰恩康于2025年8月先后召开董事会、监事会及临时股东大会，审议通过2025年员工持股计划相 关议案，为计划落地奠定坚实基础。截至2025年9月22日，该计划通过二级市场集中竞价方式，累计买 入公司股票539.6243万股，占公司总股本的1.27%，成交总金额近1.98亿元（不含交易费用），成交均 价36.69元/股，实际认购份额严格控制在股东大会审议通过的上限范围内，操作合规且高效。 公司董事长郑汉杰先生表示："员工持股计划圆满落地，是公司'以人为本、共享发展'理念的生动实 践。员工对公司未来战略前景的高度认同与坚定信心，是公司最宝贵的财富和无形的驱动力。我们将持 续聚焦核心战略，提升经营效能，以更亮眼的成绩回报全体股东的信任。" 泰恩康此次员工持股计划的顺利落地，极大激发了创新活力与奋斗激情，为后续业务拓展、技术创新注 入更强动力，为实现高质量发展奠定坚实基础。该计划的成功实施，有望成为驱动泰恩康实现新一轮高 质 ...

格隆汇9月22日丨泰恩康(301263.SZ)公布，截至2025年9月22日，2025年员工持股计划已通过二级市场 集中竞价方式累计买入公司股票5,396,243股，占公司总股本的1.27%，成交金额合计197,967,478.50元 （不含交易费用），成交均价为36.69元/股。本持股计划实际认购份额未超过公司股东大会审议通过的 拟认购份额上限。 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-067 广东泰恩康医药股份有限公司 关于 2025 年员工持股计划完成股票购买的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 1、公司控股股东、实际控制人未参加本员工持股计划，本员工持股计划未 与公司控股股东、实际控制人签署一致行动协议或存在一致行动安排。 2、公司部分董事（不含独立董事）、高级管理人员持有本员工持股计划份 额，在公司股东大会、董事会审议本员工持股计划相关提案时相关人员均均回 避表决。本员工持股计划未与公司董事、高级管理人员签署一致行动协议或存 在一致行动安排。 3、持有人会议为本员工持股计划的最高权利机构，持有人会议选举产生管 理委员会，监督本员工持股计划的日常管理，本员工持股计划持有人持有的份 额相对分散，任意单一持有人均无法对持有人会议及管理委员会决策产生重大 影响。 广东泰恩康医药股份有限公司（以下简称"公司"）分别于 2025 年 8 月 4 日、2025 年 8 月 20 日召开了第五届董事会第九次会议、第五届监事会第九次会 议及 2025 年第一次临时股东大会，审 ...

Group 1 - The core viewpoint of the news is that the weight loss drug sector experienced a significant decline in stock prices after an initial rise, indicating volatility in this market segment [1] - Specifically, Borui Pharmaceutical saw a drop of over 10% after previously rising more than 9% [1] - Other companies in the sector, such as Zhongsheng Pharmaceutical, fell over 7%, while Tianenkang, Kexing Pharmaceutical, Baihua Pharmaceutical, and Jinkaishengke also experienced declines [1]

Core Viewpoint - The company held an investor meeting to discuss new drug development, dividend plans, and profit enhancement strategies, highlighting its commitment to innovation and shareholder returns [1]. New Drug Development Progress - Investors showed significant interest in the company's new drug development, particularly the Phase III clinical trial for CKBA targeting vitiligo, which is expected to start by the end of 2025 [2]. - The IIT study for vitiligo in children aged 2-12 is progressing steadily, with data expected to be released in Q4 of this year [2]. - The company plans to initiate clinical trials for CKBA in treating rosacea as soon as it receives the II/III seamless adaptive trial approval [2]. - CKBA is positioned as a first-in-class innovative small molecule drug with substantial potential in autoimmune diseases, with plans to expand research into multiple indications [2]. - The company will keep stakeholders updated on drug approval progress and will consider orphan drug application requirements for CKBA if it proves effective and safe for children [2]. Dividend and Profit Planning - The company confirmed a stable cash dividend policy, announcing a plan to distribute 2 yuan per 10 shares for the 2024 fiscal year, with future plans to adjust based on actual conditions [3]. - Due to increased market competition, the company reported a decline in revenue and gross margin, leading to short-term performance pressure [3]. - To drive profit growth, the company aims to advance CKBA's clinical trials, launch specialty generic drugs like compound sodium sulfate tablets, and accelerate the domestic production of gastrointestinal medications [3]. Employee Stock Ownership Plan Disclosure - The company is in the stock purchase phase of its employee stock ownership plan, which will be disclosed monthly for six months following shareholder meeting approval [4].

Group 1: Clinical Trials and Research Progress - The company is actively promoting the CKBA clinical trial for vitiligo, aiming to start by the end of 2025 [2] - The IIT study for vitiligo in children aged 2-12 is progressing, with data expected in Q4 of this year [2] - The company plans to initiate clinical trials for CKBA in treating rosacea once the II/III phase trial approval is obtained [3] Group 2: Financial Performance and Dividends - The company has maintained a stable cash dividend ratio, proposing a dividend of 2 CNY per 10 shares for the 2024 fiscal year [4] - Recent increases in R&D investment and declining sales in men's health products have led to short-term performance pressure [5] - The company is focusing on launching high-potential generic drugs to create new profit growth points [5] Group 3: Employee Stock Plan and Disclosure - The employee stock plan will disclose purchase details monthly for six months after approval at the shareholders' meeting [5] - The company is committed to adhering to disclosure regulations regarding the employee stock plan [5] - No undisclosed significant information was revealed during the earnings presentation [6]